Skip to content
Screener

Ligand Pharmaceuticals LGND Total Cost of Revenue

Discontinued — last reported Q3 '19

Total Cost of Revenue at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$2.74M-34.0%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$4.61M+4.5%
Opko Health logo
Opko HealthOPK
$83.56M-22.2%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$1.53M-87.7%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$2.21M+91.9%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$3.73B+10.5%

Other financials

Income statement

See full
Revenue$63.7M+33.7%
Operating income$8.6M+1.7%
Net income$48.5M+901%
EPS (diluted)$2.22+825%

Balance sheet

See full
Cash & equivalents$1.0B+1,388%
Total debt$1.1B+19,605%
Total equity$967.5M+16.9%
Total assets$2.2B+130%

Cash flow

See full
Operating cash flow$24.0M+52.0%
CapEx$26.0K-87.9%
Free cash flow$24.0M+53.9%

Valuation

See full
Market cap$6.02B+119%
Enterprise value$6.14B+129%
P/E30.5×
P/S20.7×+6.1×

Profitability

See full
Gross margin91.9%
Operating margin32.6%+24.0pp
Net margin67.9%+49.4pp
FCF margin45.2%+16.7pp

Returns & leverage

See full
Return on equity22%+16.9pp
Debt / equity1.2×+1.2×
Current ratio31.2×+25.7×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.

The source filing: Ligand Pharmaceuticals’s 10-Q, filed November 8, 2019. Open the filing →

Filed
Nov 8, 2019
Fiscal quarter
Q3 FY2019
Calendar quarter
Q3 2019
Accession
0000886163-19-000199

FAQ

What does total cost of revenue mean?
The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.